MEDIA


stdClass Object ( [ID] => 474 [post_author] => 1 [post_date] => 2018-02-26 13:24:40 [post_date_gmt] => 2018-02-26 10:24:40 [post_content] =>

UCG has launched production of rubber cables at its facility in Podolsk, Moscow region. The new production area is equipped with state-of-the-art extrusion lines supplied by Troester, Germany. With the launch of rubber cable production UCG is able to offer a full range of specialty cables for naval and civil shipbuilding, offshore oil&gas and other demanding industrial applications.

[post_title] => UCG has launched production of rubber cables [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ucg-has-launched-production-of-rubber-cables [to_ping] => [pinged] => [post_modified] => 2018-03-30 13:26:37 [post_modified_gmt] => 2018-03-30 10:26:37 [post_content_filtered] => [post_parent] => 35 [guid] => http://wintercapital.com/?page_id=474 [menu_order] => 0 [post_type] => page [post_mime_type] => [comment_count] => 0 )
February 26
UCG has launched production of rubber cables
stdClass Object ( [ID] => 470 [post_author] => 1 [post_date] => 2017-09-14 12:00:24 [post_date_gmt] => 2017-09-14 09:00:24 [post_content] =>

Petrovax has successfully finalized clinical trials of Grippol® Quadrivalent – the first Russian influenza vaccine that protects against 4 strains of influenza virus.

Quadrivalent influenza vaccines have been recommended by the WHO since 2012. Currently, only five countries in the world manufacture quadrivalent vaccines, namely Australia, USA, Canada, Germany, and France. Russia will be the sixth country to independently manufacture such vaccine.

More on petrovax.com

[post_title] => Petrovax has successfully finalized clinical trials of Grippol® Quadrivalent [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => petrovax-has-successfully-finalized-clinical-trials-of-grippol-quadrivalent [to_ping] => [pinged] => [post_modified] => 2017-12-06 12:24:32 [post_modified_gmt] => 2017-12-06 09:24:32 [post_content_filtered] => [post_parent] => 35 [guid] => http://wintercapital.com/?page_id=470 [menu_order] => 0 [post_type] => page [post_mime_type] => [comment_count] => 0 )
September 14
Petrovax has successfully finalized clinical trials of Grippol® Quadrivalent
WINTER CAPITAL

an investment advisory firm
focused on private equity and
venture capital in Russia and Europe

KEY FACTS
APPROACH
  • Genuine partners, not merely financial investors
  • Open to any interesting investment idea
  • Long-term capital providers